[go: up one dir, main page]

JP2006522008A - ウイルス疾患および肝線維症の治療のためのインターフェロン薬物治療 - Google Patents

ウイルス疾患および肝線維症の治療のためのインターフェロン薬物治療 Download PDF

Info

Publication number
JP2006522008A
JP2006522008A JP2004569227A JP2004569227A JP2006522008A JP 2006522008 A JP2006522008 A JP 2006522008A JP 2004569227 A JP2004569227 A JP 2004569227A JP 2004569227 A JP2004569227 A JP 2004569227A JP 2006522008 A JP2006522008 A JP 2006522008A
Authority
JP
Japan
Prior art keywords
ifn
treatment
administered
amount
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004569227A
Other languages
English (en)
Japanese (ja)
Inventor
ローレンス エム． ブラット
ヘンリー エイチ． シュウ
Original Assignee
インターミューン インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターミューン インコーポレイティッド filed Critical インターミューン インコーポレイティッド
Priority claimed from PCT/US2003/041369 external-priority patent/WO2004078207A1/en
Publication of JP2006522008A publication Critical patent/JP2006522008A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004569227A 2003-02-28 2003-12-23 ウイルス疾患および肝線維症の治療のためのインターフェロン薬物治療 Pending JP2006522008A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2003/006687 WO2004078194A1 (en) 2003-02-28 2003-02-28 Interferon drug therapy for the treatment of viral diseases and liver fibrosis
PCT/US2003/032539 WO2004078193A1 (en) 2003-02-28 2003-10-14 Interferon drug therapy for the treatment of viral diseases and liver fibrosis
PCT/US2003/041369 WO2004078207A1 (en) 2003-02-28 2003-12-23 Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Publications (1)

Publication Number Publication Date
JP2006522008A true JP2006522008A (ja) 2006-09-28

Family

ID=32961111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004569227A Pending JP2006522008A (ja) 2003-02-28 2003-12-23 ウイルス疾患および肝線維症の治療のためのインターフェロン薬物治療

Country Status (5)

Country Link
JP (1) JP2006522008A (zh)
CN (1) CN1764475A (zh)
AU (2) AU2003225670A1 (zh)
CA (1) CA2516776A1 (zh)
WO (2) WO2004078194A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034764B2 (en) * 2003-10-21 2011-10-11 Medtronic Minimed, Inc. Modulation of SOCS expression in therapeutic regimens
JP2008519840A (ja) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
EP2167485B1 (en) 2007-05-31 2015-09-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX337396B (es) 2007-10-05 2016-03-02 Genzyme Corp Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica.
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
RU2578947C2 (ru) 2008-10-03 2016-03-27 Джензайм Корпорейшн Ингибиторы глюкозилцерамидсинтазы 2-ациламинопропанольного типа
RU2398582C1 (ru) * 2009-01-19 2010-09-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) * 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon

Also Published As

Publication number Publication date
AU2003225670A1 (en) 2004-09-28
CA2516776A1 (en) 2004-09-16
AU2003287145A1 (en) 2004-09-28
WO2004078193A1 (en) 2004-09-16
WO2004078194A1 (en) 2004-09-16
CN1764475A (zh) 2006-04-26

Similar Documents

Publication Publication Date Title
US20090068142A1 (en) Compositions and methods for treating coronavirus infection and sars
JP2006522008A (ja) ウイルス疾患および肝線維症の治療のためのインターフェロン薬物治療
US20090226400A1 (en) Continuous delivery methods for treating hepatitis virus infection
WO2006016930A2 (en) Methods for treating hcv infection
US20070072181A1 (en) Combination therapy for treating alphavirus infection and liver fibrosis
KR20050030886A (ko) 다단계 인터페론 전달 프로필로 간염 바이러스 감염의 치료 방법
JP2003246750A (ja) 持続的低用量サイトカイン注入治療
US20050095224A1 (en) Compositions and method for treating hepatitis virus infection
US20070258946A1 (en) Combination Therapy for Treating Hepatitis C Virus Infection
US7932267B2 (en) Use of α-glucosidase inhibitors to treat alphavirus infections
EP1596883A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2005038056A1 (en) Combination therapy for the treatment of viral diseases
WO2005062949A2 (en) Method for treating hepatitis virus infection
US20060198823A1 (en) Compositions and methods for treating viral infections
WO2005039598A1 (en) Method of treating alcoholic liver disease
WO2005123113A2 (en) Interferon compositions and methods of use thereof
WO2005016288A2 (en) Methods and compositions for treatment of viral diseases
US20070154454A1 (en) Compositions and methods for treating poxvirus infection
Barnard Pegasys
AU2002327759A1 (en) Method of treating hepatitis virus infection with a multiphasic interferon delivery profile